TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00994136
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
Study: NCT04536662
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
Study: NCT01717222
Drug: Intraperitoneal Lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 100 ml of 0.2% lignocaine
Study: NCT01717222
Drug: Intravenous Lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
Study: NCT00360568
Drug: Levodopa-carbidopa intestinal gel
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
Study: NCT05555238
Drug: single arm, single group(No interventional)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Newvast® Tab, 10 to 80 mg daily administered per the locally approved product information)
Study: NCT01275144
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01275144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03552991
Drug: Agiocur Pregranules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
Study: NCT01656252
Drug: Phase II- Sequence B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag.
Study: NCT01004055
Drug: ACTICOAT™ Antimicrobial Barrier Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing changes every 2-3 days, more frequently if needed
Study: NCT03821701
Drug: ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choose one of ACEI/ARB according to the clinical condition among the whole study.
Study: NCT03483259
Drug: Sulfatinib R capsule
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
Study: NCT05148637
Drug: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
Study: NCT02589145
Drug: Caphosol
Normalized name: Caphosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Study: NCT02589145
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by vein or mouth three times a day from Day -1
Study: NCT01423864
Drug: solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
Study: NCT01673178
Drug: 50 mg PF-05231023
Normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg IV once a week for 4 weeks
Study: NCT01673178
Drug: 100 mg PF-05231023
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg IV once a week for 4 weeks
Study: NCT01673178
Drug: 150 mg PF-05231023
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg IV once a week for 4 weeks
Study: NCT02874313
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment with oral antidiabetic drugs or insulin
Study: NCT00004102
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004102
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004102
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01945983
Drug: Early norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
Study: NCT01945983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
Study: NCT03158168
Drug: Candida Antigen
Normalized name: Candida antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candida Albicans Antigen injection
Study: NCT03158168
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc Sulfate injection
Study: NCT00510614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one pill twice weekly for 12 weeks
Study: NCT02819570
Drug: P.O roxithromycin 150 mg*2/d for 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02819570
Drug: P.O moxypen 500 mgx3/d for 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03896152
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: approximately 2 year of Treatment with LNP023
Study: NCT02141620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01517295
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: Standard prescribed dose Frequency: Once Duration: Once
Study: NCT03971383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets one time, 3 times a day(tid)
Study: NCT02563834
Drug: thiapalmitate tracer
Normalized name: pyridoxine dipalmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled tracer infusion; occurs in all treatment arms
Study: NCT00735007
Drug: Rebif® New Formulation (RNF) using RebiSmartTM
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNF 44 mg, 3 times a week by subcutaneous injection.
Study: NCT03179735
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Study: NCT03775434
Drug: Experimental: B244
Approvals — FDA: no, EMA: no, PMDA: no
Description: B244 suspension in 30ml/bottle
Study: NCT03693326
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 300 mg (fixed dose) intraveneously every 3 weeks
Study: NCT03814148
Drug: LENINGRADO 5 association
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 coated sustained-release tablet, oral, once a day.
Study: NCT03814148
Drug: Natrilix® SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 coated sustained-release tablet, oral, once a day.
Study: NCT03179735
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Study: NCT03044314
Drug: Iloprost and nitric oxide administration
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
Study: NCT01310868
Drug: Gliadel wafers
Approvals — FDA: no, EMA: no, PMDA: no
Description: The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
Study: NCT03664115
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes
Study: NCT03834363
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanylpatch 12 mcg/hr, change patch every three days.
Study: NCT03834363
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch, change patch every three days.
Study: NCT01310868
Drug: Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Approvals — FDA: no, EMA: no, PMDA: no
Description: temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
Study: NCT00948649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
Study: NCT01310868
Drug: Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
Study: NCT00109551
Drug: iron sulphate-folic acid dietary supplement
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02546921
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
Study: NCT03834363
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule bid
Study: NCT04147260
Drug: Placebo to match BI 730357
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT02700048
Drug: Intra-nasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
Study: NCT00002535
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002535
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02743364
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00449163
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03706911
Drug: VM-1500A-LAI
Normalized name: laidlomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form
Study: NCT02546921
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Study: NCT02546921
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Study: NCT00762684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
Study: NCT01124747
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05867056
Drug: HBV HCC Module MAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose administration of IMC-I109V
Study: NCT01409239
Drug: Subcutaneous Insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: basal bolus insulin using carb counting technique and insulin analogues
Study: NCT01845779
Drug: DCF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02343575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg matched to VPA BID PO/NGT
Study: NCT02546921
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Study: NCT02546921
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Study: NCT02546921
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Study: NCT02546921
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Study: NCT00198991
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytostatic drug
Study: NCT00198991
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytostatic drug
Study: NCT00198991
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytostatic drug
Study: NCT03767829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
Study: NCT00591851
Drug: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC \[Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)\] Followed By Paclitaxel (P)
Study: NCT00387946
Drug: SSR591813L (dianicline)
Normalized name: tetracycline hydrochloride Topical Ointment [Diabecline]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00259402
Drug: Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
Study: NCT00847080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet per day per 2 weeks
Study: NCT01227200
Drug: dypiron, tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: dypiron 4 ML, tramadol 50 mg flashtab
Study: NCT01318395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once per day
Study: NCT00821717
Drug: Ferinject ® (Ferric carboxymaltose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
Study: NCT00814307
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg CP-690,550 BID PO for 6 months
Study: NCT00198991
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antileukemic drug
Study: NCT00814307
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CP-690,550 BID PO for 6 months
Study: NCT02420327
Drug: Placebo patch & placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
Study: NCT00848939
Drug: treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
Study: NCT00848939
Drug: treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
Study: NCT00814307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
Study: NCT00003489
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04133909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
Study: NCT02296333
Drug: isotonic
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intravenous in the skin closure
Study: NCT01717742
Drug: DNase
Normalized name: DNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
Study: NCT04980014
Drug: NesinaAct® Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
Study: NCT00431093
Drug: low-dose estradiol/noresterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).